Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 13/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899123 | 1.00 | ESR1 (0.63) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 | |
| SCHEMBL2835305 | 1.00 | ESR1 (0.63) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 | |
| SCHEMBL7707677 | 0.82 | ESR1 (0.48) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 | |
| SCHEMBL2832847 | 0.82 | ESR1 (0.48) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 | |
| SCHEMBL2832843 | 0.82 | ESR1 (0.48) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 | |
| SCHEMBL6899294 | 0.82 | ESR1 (0.48) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 | |
| SCHEMBL1249500 | 0.79 | ESR1 (0.63) | ESR1LMNASMN1; SMN2CYP19A1ESR2 | |
| SCHEMBL7867608 | 0.79 | ESR1 (0.63) | ESR1LMNASMN1; SMN2CYP19A1ESR2 | |
| SCHEMBL29489438 | 0.79 | ESR1 (0.63) | ESR1LMNASMN1; SMN2CYP19A1ESR2 | |
| SCHEMBL1332731 | 0.78 | ESR1 (1.00) | ESR1LMNAMAPK1SMN1; SMN2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | PHERIN PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | claimed |
| EP-0891188-A4 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARM INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | claimed |
| EP-0715517-A4 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORP (US) | 2000-10-11 | — | — | EP | claimed |
| US-6117860-A | NASALLY ADMINISTERING STEROID WHICH BINDS TO A SPECIFIC NEUROEPITHELIAL RECEPTOR FOR ALLEVIATING PREMENSTRUAL TENSION AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 2000-09-12 | — | — | US | claimed |
| US-6066627-A | ALTERING BLOOD CONCNETRATION OF LUTEINIZING HORMONE | PHERIN CORPORATION (US) | 2000-05-23 | — | — | US | claimed |
| JP-2000504025-A | — | — | 2000-04-04 | — | — | JP | claimed |
| EP-0891188-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | Pherin Pharmaceuticals, Inc. (US) | 1999-01-20 | — | — | EP | claimed |
| US-5783571-A | SUBSTITUTED TETRAENE STEROIDS FOR CONTROLLING GLANDULAR FUNCTION | PHERIN CORPORATION (US) | 1998-07-21 | — | — | US | claimed |
| EP-0715517-A1 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1994028903-A1 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1994-12-22 | — | — | WO | claimed |
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | PHERIN PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | CYP19A1, SHBG, HSD17B11 | ESR1 7/4885LMNA 2321/4885MAPK1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.